Injection of nanoparticle has proven effective in mouse models, researchers say
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. Their innovative approach has so far proven effective in preventing the development of melanoma in mouse models and in treating primary tumors and metastases that result from melanoma.
The focus of the research is on a nanoparticle that serves as the basis for the new vaccine. The study was led by Prof. Ronit Satchi-Fainaro, chair of the Department of Physiology and Pharmacology and head of the Laboratory for Cancer Research and Nanomedicine at TAU’s Sackler Faculty of Medicine, and Prof. Helena Florindo of the University of Lisbon while on sabbatical at the Satchi-Fainaro lab at TAU; it was conducted by Dr. Anna Scomparin of Prof. Satchi-Fainaro’s TAU lab and postdoctoral fellow Dr. João Conniot. The results were published on August 5 in Nature Nanotechnology.
Melanoma develops in the skin cells that produce melanin or skin pigment. “The war against cancer in general, and melanoma in particular, has advanced over the years through a variety of treatment modalities, such as chemotherapy, radiation therapy and immunotherapy; but the vaccine approach, which has proven so effective against various viral diseases, has not materialized yet against cancer,” says Prof. Satchi-Fainaro. “In our study, we have shown for the first time that it is possible to produce an effective nano-vaccine against melanoma and to sensitize the immune system to immunotherapies.”
The researchers harnessed tiny particles, about 170 nanometers in size, made of a biodegradable polymer. Within each particle, they “packed” two peptides — short chains of amino acids, which are expressed in melanoma cells. They then injected the nanoparticles (or “nano-vaccines”) into a mouse model bearing melanoma.
“The nanoparticles acted just like known vaccines for viral-borne diseases,” Prof. Satchi-Fainaro explains. “They stimulated the immune system of the mice, and the immune cells learned to identify and attack cells containing the two peptides — that is, the melanoma cells. This meant that, from now on, the immune system of the immunized mice will attack melanoma cells if and when they appear in the body.”
The researchers then examined the effectiveness of the vaccine under three different conditions.
First, the vaccine proved to have prophylactic effects. The vaccine was injected into healthy mice, and an injection of melanoma cells followed. “The result was that the mice did not get sick, meaning that the vaccine prevented the disease,” says Prof. Satchi-Fainaro.
Second, the nanoparticle was used to treat a primary tumor: A combination of the innovative vaccine and immunotherapy treatments was tested on melanoma model mice. The synergistic treatment significantly delayed the progression of the disease and greatly extended the lives of all treated mice.
Finally, the researchers validated their approach on tissues taken from patients with melanoma brain metastases. This suggested that the nano-vaccine can be used to treat brain metastases as well. Mouse models with late-stage melanoma brain metastases had already been established following excision of the primary melanoma lesion, mimicking the clinical setting. Research on image-guided surgery of primary melanoma using smart probes was published last year by Prof. Satchi-Fainaro’s lab.
“Our research opens the door to a completely new approach — the vaccine approach — for effective treatment of melanoma, even in the most advanced stages of the disease,” concludes Prof. Satchi-Fainaro. “We believe that our platform may also be suitable for other types of cancer and that our work is a solid foundation for the development of other cancer nano-vaccines.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indicationson January 13, 2020 at 7:13 am
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, reported today, at the 38th JP Morgan ...
- Melanoma patients report 95% satisfaction rate with Mohs surgeryon January 12, 2020 at 10:39 am
Patients who received Mohs surgery to treat the most serious form of skin cancer, melanoma, reported a 95 percent long-term satisfaction rate with their results, according to a new study by UT ...
- Rise of immune therapy for melanoma a 'revolution' in treatmenton January 12, 2020 at 8:44 am
They lodge in different parts of the body, including lymph nodes and other organs, like the liver or lungs, sometimes the brain." Once there, the melanoma cancer cells set up "colonies" and keep ...
- Researchers identify molecular characteristics of leptomeningeal melanoma metastaseson January 10, 2020 at 9:46 am
Patients with advanced melanoma who develop metastases in the leptomeninges, the fluid filled membranes surrounding the brain and spinal cord, have an extremely dismal prognosis. Most patients only ...
- Doctor who spent career researching melanoma dies from the disease after spotting changes to a mole on her neckon January 10, 2020 at 8:38 am
A doctor who spent her career investigating the causes and treatment options for melanoma has died from the disease after noticing changes to a mole on her neck. Dr Sharon Hutchinson, who worked as a ...
- Metastatic Melanoma Drug Market Emerging Analysis, Future Growth And Business Opportunities 2026on January 9, 2020 at 11:08 pm
As the competition soars in the global Metastatic Melanoma Drug market, an increasing number of companies are looking exclusive insights into the prevailing trends in the market. Ameco Research study ...
- AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanomaon January 9, 2020 at 9:19 am
Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer and clinically challenging due to its propensity to develop therapy resistance. Reactive oxygen species (ROS) can induce DNA ...
- Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cellson January 9, 2020 at 2:30 am
The study population consists of 12 melanoma patients and 6 healthy donors (HDs) used as controls. Selected characteristics of all subjects are listed in STable 1. Age at blood draw did not differ ...
- Let's Talk About Melanomaon January 8, 2020 at 8:08 am
Whether you’ve just been diagnosed or worry you could have melanoma, you’re probably nervous, confused, and likely scared. We get it: Melanoma is a form of skin cancer that can be life-threatening.
- Melanoma Immunotherapy Enhanced by Targeting Treg Cell Control Proteinon January 8, 2020 at 5:19 am
For some people with advanced melanoma, such treatment has extended survival from months, to years. However, therapy is only effective in about 40% of people with advanced melanoma. Ze’ev Ronai, Ph.D.
via Bing News